We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epistem Announces Research and Development Collaboration with Novartis
News

Epistem Announces Research and Development Collaboration with Novartis

Epistem Announces Research and Development Collaboration with Novartis
News

Epistem Announces Research and Development Collaboration with Novartis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epistem Announces Research and Development Collaboration with Novartis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem Plc has announced that it has signed a research and development collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas.

The collaboration combines Epistem’s stem cell expertise and drug discovery programme, with Novartis’s insights into disease pathways & bioinformatics.

Under the terms of the agreement, Novartis will pay Epistem an upfront cash payment of $4.0 million and will provide research funding for 2 years. Novartis has an option to exclusively license targets for development of biotherapeutic products in exchange for license fees, milestone payments and royalties.

For each product developed from targets licensed under the agreement, Epistem is eligible to receive up to $45.0 million in milestones. Furthermore, if leads are commercialized Epistem is eligible to receive tiered royalties on worldwide sales.

Matthew Walls, Epistem CEO, commented: “The collaboration will enable us to accelerate the development of our existing targets with a world class pharmaceutical collaborator and to jointly explore disease opportunities in regenerative medicine”.

Dr Jeffrey Moore, Novel Therapies Division Managing Director said: “The collaboration will leverage each group’s strengths to make novel discoveries leading to advances in treating unmet medical needs across several disease areas”.
Advertisement